NOVENTA, FRANCO
 Distribuzione geografica
Continente #
NA - Nord America 5.534
EU - Europa 602
AS - Asia 559
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 1
SA - Sud America 1
Totale 6.704
Nazione #
US - Stati Uniti d'America 5.524
CN - Cina 286
SG - Singapore 187
DE - Germania 134
FI - Finlandia 124
UA - Ucraina 80
SE - Svezia 71
VN - Vietnam 70
GB - Regno Unito 55
FR - Francia 54
IT - Italia 42
IE - Irlanda 14
IN - India 11
RU - Federazione Russa 8
MX - Messico 6
ES - Italia 5
NL - Olanda 4
CA - Canada 3
EU - Europa 3
NZ - Nuova Zelanda 3
BG - Bulgaria 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
HK - Hong Kong 2
AU - Australia 1
BZ - Belize 1
EC - Ecuador 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
IS - Islanda 1
JP - Giappone 1
NG - Nigeria 1
PT - Portogallo 1
RS - Serbia 1
TR - Turchia 1
Totale 6.704
Città #
Fairfield 944
Woodbridge 554
Houston 499
Jacksonville 429
Ann Arbor 406
Ashburn 355
Wilmington 336
Chandler 318
Seattle 307
Cambridge 292
Princeton 156
Singapore 146
Boardman 124
San Diego 82
Santa Clara 82
Dong Ket 70
Beijing 61
Roxbury 57
Nanjing 52
Helsinki 42
Medford 31
Des Moines 28
Guangzhou 23
Jiaxing 17
Shenyang 14
Dublin 13
Hebei 13
Nanchang 12
London 11
Tianjin 11
New York 10
Padova 10
Changsha 9
Redwood City 9
Falls Church 7
Hefei 7
Norwalk 7
San Jose 7
Jinan 6
Monterrey 6
Kilburn 5
Nürnberg 5
Bologna 4
Kharkiv 4
Los Angeles 4
Prescot 4
Shanghai 4
Dearborn 3
Indiana 3
Las Vegas 3
Ogden 3
Zhengzhou 3
Chicago 2
Coimbatore 2
Dallas 2
Frankfurt am Main 2
Fremont 2
Fuzhou 2
Hong Kong 2
Leawood 2
Majadahonda 2
Munich 2
Pune 2
Qingdao 2
Roanoke 2
San Francisco 2
Santander 2
Sofia 2
Washington 2
Yellow Springs 2
Acton 1
Aigaleo 1
Auburn Hills 1
Augusta 1
Belgrade 1
Belize City 1
Bolzano 1
Borås 1
Bristol 1
Brno 1
Buffalo 1
Chengdu 1
Chongqing 1
Columbus 1
Düsseldorf 1
Falkenstein 1
Geneva 1
Girard 1
Greenwich 1
Haikou 1
Hangzhou 1
Honolulu 1
Jerusalem 1
Kilkenny 1
Kunming 1
Lagos 1
Lanzhou 1
Lappeenranta 1
Lisbon 1
Madrid 1
Totale 5.674
Nome #
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score 157
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. 143
Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study 143
A venous thromboembolism risk assessment model for patients with Cushing’s syndrome 136
Antibody profile and clinical course in primary anti phospholipid syndrome with pregnancy morbidity 134
Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. 132
Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. 128
A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses 124
LONG-TERM OUTCOME OF CHRONIC TYPE-B HEPATITIS IN PATIENTS WHO ACQUIRE HEPATITIS-B VIRUS-INFECTION IN CHILDHOOD 120
COVID-19 and Venous Thromboembolism in Intensive Care or Medical Ward 105
Open Repair for Ruptured Abdominal Aortic Aneurysm: Is It Possible to Predict Survival? 104
Detection of immunoglobulins G and A on the cell membrane of hepatocytes from patients with alcoholic liver disease. 103
Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study 101
Long-term use of vitamin K antagonists and incidence of cancer: a population-based study 100
Fibrosis progression in initially mild chronic hepatitis C 100
HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND HEPATITIS-C PATHOLOGY 99
P53 OVEREXPRESSION IN THE MULTISTEP PROCESS OF ESOPHAGEAL CARCINOGENESIS 97
Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. 94
Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes 94
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. 94
SAFE Biopsy: A Validated Method for Large-Scale Staging of Liver Fibrosis in Chronic Hepatitis C 94
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone 92
A new integrated approach to improve left ventricular electromechanical activation during right ventricular septal pacing 91
Left Ventricular Dyssynchrony Resulting from Right Ventricular Apical Pacing: Relevance of Baseline Assessment 90
Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study 90
Anti-beta(2)-glycoprotein I ELISA assay: The influence of different antigen preparations 89
Antibody profiles for the diagnosis of antiphospholipid syndrome 89
Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism. 89
A model to predict long-term sustained response to interferon therapy in chronic hepatitis C 88
Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C 87
Therapy of hepatitis C: re-treatment with alpha interferon. 86
The changing epidemiology of acute type B hepatitis: results of an 11-year prospective study in Padua (northern Italy). 86
Simultaneous surgical treatment of abdominal aortic aneurysm and carcinoma of the bladder 85
Role of aneurysm sac embolization during endovascular aneurysm repair in the prevention of type II endoleak-related complications 85
NATURAL HISTORY AND PROGNOSTIC FACTORS OF CHRONIC HEPATITIS TYPE B 85
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C 84
Aspirin and recurrent venous thromboembolism 83
Diagnostic performance of noninvasive biomarkers of liver fibrosis and cirrhosis in chronic hepatitis B 80
Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance 80
Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study 80
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients 78
Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon 78
Variability of Left Ventricular Electromechanical Activation during Right Ventricular Pacing: Implications for the Selection of the Optimal Pacing Site 78
Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome 75
Role of Intraoperative Aneurysm Sac Embolization during EVAR in the Prevention of Type II Endoleak 74
A scoring system to predict the risk of hepatocellular carcinoma (HCC) in patients with compensated cirrhosis. 72
HEPATITIS C VIRAEMIA AND LIVER DISEASE IN SYMPTOM-FREE INDIVIDUALS WITH ANTI-HCV 72
Prevalence of Liver Disease in a Population of Asymptomatic Persons with Hepatitis C Virus Infection 72
Post-transfusion hepatitis in Italy. 72
High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. 71
Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. 69
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. 69
Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome 69
Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation 68
Microsomal triglyceride transfer protein (MTP) gene polymorphism and lipid metabolism in HCV-infected patients 68
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. 66
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis 64
Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment 62
VIRUS RECEPTORS FOR POLYMERIZED HUMAN SERUM ALBUMIN (PHSA) IN HEPATITIS B VIRUS (HBV) INFECTION: DETECTION BY A SOLID PHASE RADIOIMMUNOASSAY (RIA) 60
Relationship between membrane-bound immunoglobulin and viral antigens in liver cells from patients with hepatitis B virus infection. 60
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. 60
Space-occupyng lesions of the liver detected by ultrasonography and their relation to hepatocellular carcinoma in cirrhosis 59
The diagnostic performance of different non-invasive markers of liver fibrosis (LF) varies according to etiology of liver disease 58
Histology and virus replication in the liver: a prognostic puzzle in chronic hepatitis B. 58
Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal va¬rices. 58
Variables that influence response to different interferon schedules in chronic hepatitis C and predictive models. 57
PROBLEMS IN THE MANAGEMENT OF CHRONIC HEPATITIS-B WITH INTERFERON - EXPERIENCE IN A RANDOMIZED, MULTICENTER STUDY 57
Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe 56
Role of aneurysm sac embolization during EVAR in the prevention of type II endoleak related complications 56
CELLULAR IMMUNITY TO THE HEPATITIS B VIRION IN ACUTE HEPATITIS TYPE B 53
Hepatic iron in chronic hepatitis C: The effect of different HCV genotypes 52
Combination of non invasive markers to identify liver fibrosis in HCV patients with persistently normal ALT (PNALT) 49
The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study 48
High levels of soluble TNF superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. 43
Therapy for chronic hepatitis B with lymphoblastoid interferon-alpha and levamisole. 43
Prognostic indicators of survival in patients with cirrhosis and esophageal varices, without pre¬vious bleeding 43
The natural history of post-transfusion and sporadic non-A, non-B, hepatitis in Italy. 42
Pegylated interferon-associated retinopathy is frequent in HCV patients with hypertension and justifies ophthalmologic screening. 41
Determinants of disease activity and evolution of chronic hepatitis type B. 40
MAC Project-Monitoring Anticoagulant Therapy Observational Study: Rationale and Protocol 40
Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience 39
Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation 38
Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. 38
Low-Molecular-Weight Heparin versus Compression Stockings for Thromboprophylaxis after Knee Arthroscopy: A Randomized Trial. 37
Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project 34
Cryptogenic chronic liver disease and serum or liver hepatitis B virus markers. Their possible correlations and etiologic significance. 33
Changes in liver membrane antigenicity and intracellular viral antigens expression in hepatitis B virus-infected hepatocytes. 32
Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study 30
Totale 6.732
Categoria #
all - tutte 24.748
article - articoli 24.532
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.280


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020769 0 0 0 0 0 0 134 164 159 167 55 90
2020/20211.029 34 78 16 58 63 117 28 89 174 107 119 146
2021/20221.173 23 133 147 100 38 77 63 126 51 31 159 225
2022/2023699 167 65 6 74 136 97 3 35 60 5 28 23
2023/2024315 16 53 34 27 21 26 18 14 9 6 43 48
2024/2025477 1 88 87 39 227 34 1 0 0 0 0 0
Totale 6.732